0
Skip to Content
The Pharma xCentric
The Pharma xCentric
About us
Our Mission
News-Press
Weekly Spotlight
Newsletter
Online Broadcasts
Keynotes
The xCentric Podcast
Webinar Series
Patient-Centric Platforms
Contact us
The Pharma xCentric
The Pharma xCentric
About us
Our Mission
News-Press
Weekly Spotlight
Newsletter
Online Broadcasts
Keynotes
The xCentric Podcast
Webinar Series
Patient-Centric Platforms
Contact us
About us
Our Mission
Folder: News-Press
Back
Weekly Spotlight
Newsletter
Folder: Online Broadcasts
Back
Keynotes
The xCentric Podcast
Webinar Series
Patient-Centric Platforms
Contact us
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #18 πŸ“’
Review Article Nelio Drumond 8/27/24 Review Article Nelio Drumond 8/27/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #18 πŸ“’

Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #17 πŸ“’
Review Article Nelio Drumond 8/6/24 Review Article Nelio Drumond 8/6/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #17 πŸ“’

Patient‑Centric Drug Development Comes of Age

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #16 πŸ“’
Review Article Nelio Drumond 7/30/24 Review Article Nelio Drumond 7/30/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #16 πŸ“’

Patient-Focused Drug Development: A New Direction for Collaboration

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #15 πŸ“’
Review Article Nelio Drumond 5/30/24 Review Article Nelio Drumond 5/30/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #15 πŸ“’

Outside-In: Why Putting Patients at the Heart of Drug Development Matters

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #14 πŸ“’
Expert Opinion Nelio Drumond 4/23/24 Expert Opinion Nelio Drumond 4/23/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #14 πŸ“’

Patient-Centered Drug Delivery Innovation

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #13 πŸ“’
Expert Opinion Nelio Drumond 4/16/24 Expert Opinion Nelio Drumond 4/16/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #13 πŸ“’

Improved therapeutic outcomes through better dose design

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #12 πŸ“’
Research Article Nelio Drumond 4/9/24 Research Article Nelio Drumond 4/9/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #12 πŸ“’

Patient-Centric drug product design in modern drug delivery as an opportunity to increase safety and effectiveness

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #11 πŸ“’
Research Article Nelio Drumond 4/2/24 Research Article Nelio Drumond 4/2/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #11 πŸ“’

Patient Centricity and Pharmaceutical Companies: Is it Feasible?

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #10 πŸ“’
Research Article Nelio Drumond 3/26/24 Research Article Nelio Drumond 3/26/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #10 πŸ“’

Defining Patient-Centric Pharmaceutical Drug Product Design

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #9 πŸ“’
Expert Opinion Nelio Drumond 3/19/24 Expert Opinion Nelio Drumond 3/19/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #9 πŸ“’

Patient-Focused Drug Development: To Understand Patients, You Must Engage Them

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #8 πŸ“’
Expert Opinion Nelio Drumond 3/12/24 Expert Opinion Nelio Drumond 3/12/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #8 πŸ“’

Why Putting Patients at the Center of Drug Development Really Matters

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #7 πŸ“’
Expert Opinion Nelio Drumond 3/5/24 Expert Opinion Nelio Drumond 3/5/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #7 πŸ“’

Patient-Centric Drug Development: Designing Medicines to Succeed

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #6 πŸ“’
Expert Opinion Nelio Drumond 2/27/24 Expert Opinion Nelio Drumond 2/27/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #6 πŸ“’

Patient-Centric Design: The Next Frontier In Drug Delivery

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #5 πŸ“’
Patient-Centric Drug Product Development Nelio Drumond 2/20/24 Patient-Centric Drug Product Development Nelio Drumond 2/20/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #5 πŸ“’

Scientific evidence for acceptability of minitablets in pediatrics: Part II

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #4 πŸ“’
Patient-Centric Drug Product Development Nelio Drumond 2/13/24 Patient-Centric Drug Product Development Nelio Drumond 2/13/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #4 πŸ“’

Scientific evidence for acceptability of minitablets in pediatrics

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #3 πŸ“’
Patient-Centric Drug Product Development Nelio Drumond 2/6/24 Patient-Centric Drug Product Development Nelio Drumond 2/6/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #3 πŸ“’

Revolutionizing pediatric medication: Minitablets in the spotlight!

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #2 πŸ“’
Regulatory Nelio Drumond 1/30/24 Regulatory Nelio Drumond 1/30/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #2 πŸ“’

Navigating Pediatric Medicines Development: EMA Guideline

Read More
π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #𝟭 πŸ“’
Regulatory Nelio Drumond 1/23/24 Regulatory Nelio Drumond 1/23/24

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #𝟭 πŸ“’

Exploring the Roots of Patient-Centric Drug Product Design

Read More